Two of Cannabis’s Largest Private Operators Just Signaled the MSO Shakeout Is Real

Within 48 hours, Cannabist filed for insolvency protection and PharmaCann announced it’s abandoning Colorado. This is what a forced consolidation looks like.

The multi-state operator model was built on a theory: scale wins. Get licensed in enough states, integrate vertically, and eventually the federal thaw comes and you’re positioned to dominate. The math is not working out.

In the span of 48 hours last week, two of the cannabis industry’s largest private operators made moves that strip that theory down to its balance sheet. The Cannabist Company filed for insolvency protection under Canada’s Companies’ Creditors Arrangement Act while announcing the sale of assets in eight states. PharmaCann — parent of Colorado’s LivWell — told state authorities it’s closing its Denver cultivation operation and laying off 132 workers, permanent closure set for May 20.

These aren’t isolated distress signals. They’re the same signal arriving in different envelopes.

Cannabist: Orderly Exit or Controlled Collapse?

On March 23, The Cannabist Company Holdings Inc. (Cboe CA: CBST; OTCQB: CBSTF) announced it had entered definitive agreements to sell its Ohio operations to Holistic Industries for $47 million — $34.5 million in cash plus a $12.5 million promissory note — and its Delaware assets to Parma Holdco LLC, a Boston-based investment fund affiliate, for $16.5 million cash.

That same day, the company commenced CCAA proceedings in Ontario Superior Court and signaled it would pursue Chapter 15 recognition in U.S. bankruptcy court. It also disclosed a non-binding memorandum of understanding to sell “certain production, manufacturing, distribution and sale operations” in six additional states: Illinois, New Jersey, Colorado, Massachusetts, Maryland, and West Virginia.

Markets not covered by either transaction — New York and Pennsylvania were cited — will wind down.

Cannabist, formerly Columbia Care before a 2023 rebrand, was once considered one of the more credible mid-tier MSOs: diversified state exposure, institutional backing, legitimate medical market depth. None of that insulated it when price compression met a balance sheet that couldn’t service its debt load through a multi-year contraction.

The Ohio sale to Holistic Industries is the transaction worth watching. Holistic is a privately held, vertically integrated operator with strength in Pennsylvania, Maryland, and Massachusetts. Picking up Cannabist’s Ohio infrastructure for $47 million — in a state that’s now adult-use and closing in on 400 licensed dispensaries — is either a savvy distressed acquisition or a bet that Ohio’s market stabilizes faster than the seller’s financials did. Given Holistic’s track record, probably both.

PharmaCann: The LivWell Bet Goes Wrong

PharmaCann’s Colorado retreat has a different shape but a similar root cause.

The Chicago-based MSO acquired LivWell Enlightened Health in 2022 in an all-stock deal, gaining one of Colorado’s largest cultivation and retail footprints. The economics of that deal were always contingent on Colorado holding ground. It hasn’t.

Colorado cannabis sales peaked at roughly $2.2 billion in 2021. By 2025, that number was $1.3 billion — a 40% drop from peak over four years. PharmaCann filed a WARN Act notice with the state in March indicating it will permanently close its cultivation and distribution facility at 5141 N. National Western Drive in Denver, affecting 132 workers in cultivation, farming, data, and production roles.

The retail half of the Colorado bet has already been offloaded. In December 2025, Vireo Growth Inc. announced an agreement to acquire PharmaCann’s 41 Colorado dispensaries for $49 million in stock. Vireo, the Minneapolis-based MSO, was trading around 40 cents per share at announcement — meaning that $49 million headline figure was considerably softer in cash-equivalent terms. PharmaCann got retail off its books; it’s now exiting the cost center behind the product.

What PharmaCann is left with is unclear. The company has historically operated in Illinois, Pennsylvania, Ohio, Massachusetts, Michigan, and Maryland, in addition to Colorado. No announcement about broader strategy accompanied the facility closure notice.

The Pattern Here

The MSO model accumulated state licenses assuming one of two outcomes: federal legalization would arrive and unlock financing and interstate commerce, or state markets would continue growing into profitability. Neither happened on schedule.

What actually happened: state markets matured faster than expected, retail licenses expanded aggressively, wholesale prices collapsed, and operators who’d borrowed against future growth found themselves servicing debt inside shrinking revenue envelopes. Add 280E tax treatment, near-zero access to conventional capital markets, and the picture becomes obvious in retrospect.

What’s happening now is forced rationalization. Cannabist’s asset sales will transfer operations to operators with stronger balance sheets or more focused geographic strategy. PharmaCann’s Colorado exit opens cultivation capacity in a state already suffering from oversupply — that’s not bullish for whoever absorbs those assets. Vireo’s 41-dispensary bet on Colorado retail looks increasingly like value-buying in a still-troubled market.

The operators who survive the next 18 months are those with low debt, strong cash flow in their core markets, and optionality on federal movement without requiring it. That’s a short list.

Holistic Industries just got longer on Ohio. Who else is positioning — and for what — is the real industry story for the rest of 2026.

Caleb Quinn is Industry editor at CannabisInquirer.com.